Testing MB-001 for moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This study tests an investigational drug called MB-001 for people with moderate to severe ulcerative colitis who have already tried standard treatments without success. It aims to see if the drug is safe and helps control inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderately to severely active ulcerative colitis, confirmed by a scope test (colonoscopy or flexible sigmoidoscopy).
- You have tried at least one standard UC treatment (like 5-ASA drugs, steroids, or a biologic) that didn't work well enough, stopped working, or caused side effects.
- You have not tried more than one advanced therapy (like vedolizumab, ustekinumab, or similar) without success.
- You are not currently in a very severe flare that needs hospital care, and you have not had major colon surgery or a stoma.
- You are not pregnant or breastfeeding, and agree to use contraception during the study and for 28 days after the last dose.
- You do not have active infections (like tuberculosis, hepatitis B or C, or C. diff) that are not being treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This study tests an investigational drug called LIV001 for people with mild-to-moderate ulcerative colitis. It aims to see if the drug is safe and may help reduce inflammation in the colon.
This study tests an investigational pill for people with moderate-to-severe ulcerative colitis that has not improved with standard treatments. The goal is to see if the pill can reduce symptoms like bloody stools and frequent bowel movements.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This trial tests a new medicine, ENC1018, taken by mouth, for people with moderate to severe ulcerative colitis (UC) that hasn't improved with standard treatments. The goal is to see if it's safe and helps reduce symptoms.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.